You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Innovative Use of the Noom Monitor Mobile Application for CBT-GSH in Binge Eaters
SBC: Noom, Inc. Topic: NIMHDESCRIPTION (provided by applicant): Bulimia nervosa and binge eating disorder are marked by significant levels of impairment and psychiatric comorbidity, affecting approximately 5-7% of the US population. Guided self-help cognitive behavioral (CBT-GSH) therapy has been show to be an effective treatment to reduce binge eating for patient with both disorders. However, there is limited uptake among ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Remote focusing through spatial light modulation for multifocal multiphoton micro
SBC: BOULDER NONLINEAR SYSTEMS, INC. Topic: NIMHDESCRIPTION (provided by applicant): Nonlinear optical microscopy techniques (such as two-photon florescence) are being used to acquire volumetric (i.e. three dimensional) images that probe several hundred microns into scattering tissue. These techniques are being combined with fast acquisition schemes to allow imaging of live, moving specimens at high NA. This combination allows for high-resoluti ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Neurorestorative therapy of stroke with HUCBC in T2DM rats
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: NINDSDESCRIPTION (provided by applicant): Diabetes mellitus (DM) leads to a 3-4 fold higher risk of experiencing ischemic stroke. In addition, DM stroke patients are more prone to develop more and earlier white matter (WM) high-intensity lesions than non DM stroke patients. Treatment of stroke with tissue plasminogen activator (rtPA) at 2-3 hours after stroke decreases lesion volume in non-DM rats. How ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Fluorescence Image-Guided Near Infrared (NIR) Photodynamic Therapy (PDT) Agent
SBC: PHOTOLITEC LLC Topic: NCIDESCRIPTION (provided by applicant): Photolitec's patented technology is focused on developing improved agents for tumor- imaging, image-guided surgery and/or photodynamic therapy (PDT). The proposed STTR proposal includes fluorescence-image guided PDT, aSee and Treat approach. The fluorescence imaging compound with long wavelength absorption near 800 nm should be extremely useful for image ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of a new approach to screening for language impairments
SBC: ELLENSON INTEGRATION ENTERPRISES, INC. Topic: NIDCDDESCRIPTION (provided by applicant): This Small Business Technology and Transfer (STTR) Fast Track proposal focuses on the translation of innovative research protocols for diagnosing Specific Language Impairment (SLI) into an innovative, easy-to- use app-based screener with high potential for private sector commercialization. SLI is a form of language impairment with no known cause, with a strong ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Increasing Access and Developing Predictors for Colorectal Cancer Screening for Minority and Medicaid Clients
SBC: Witness CARES, LLC Topic: 102ABSTRACT African Americans have 22% higher incidence and 49% higher death rates from CRC than any other ethnic/racial group. Similarly, lower socioeconomic status (SES) is also associated with higher CRC incidence and mortality. Both of these groups are overrepresented in Medicaid populations. Screening colonoscopy is a cost-effective cancer prevention and control strategy, leading to CRC preventi ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques
SBC: Navidea Biopharmaceuticals, Inc. Topic: NHLBIMyocardial infarctionsMIor heart attacksischemic strokesISand peripheral artery diseasePADtogether considered cardiovascular diseaseCVDare all commonly caused by the same underlying pathologyatherosclerosisMIs and ISs are the leading causes of death and disability worldwideAtherosclerosis is a progressive pathology that develops asymptomatically over the course of many years as inflammatory plaque ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Targeting neurotoxic alpha-synuclein aggregates for Parkinson's disease therapy.
SBC: Vova Ida, LLC Topic: 999SUMMARYParkinsonandapos s diseasePDis the second most prevalent neurodegenerative disorder after Alzheimerandapos s diseaseADaffecting more thanmillion people in the United StatesBecause age is the major risk factorthe prevalence of both diseases is steadily increasing as our population agesPD belongs to the group of protein misfolding neurodegenerative diseases that are due to the misfolding and ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model
SBC: APPLIED GENETIC TECHNOLOGIES CORPORATION Topic: NDESCRIPTION provided by applicant Complete achromatopsia is an autosomal recessive inherited congenital disorder of retinal cone photoreceptors Patients with complete achromatopsia experience extreme light sensitivity and daytime blindness and best visual acuity under non bright light conditions is usually or worse and generally stable over time In addition to poor acuity hypersensit ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Targeting bacteria, the innate response of the middle ear to infection, and host-pathogen interactions, using topical and transtympanic applications for the treatment of otitis media.
SBC: EARNANO LLC Topic: NICHDOtitis media is a world wide disease primarily affecting the pediatric population under the age ofyearsIt is the most common reason for pediatric care visits and antibiotic therapyOver prescription and poorcompliance have led to a reduced susceptibility of bacteria to antibiotics andconsequentiallyto recurrent and chronic ear diseasesClearlythere is a compelling need to investigate alternative the ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health